EC Nutrition

Nattokinase has been shown to have fibrinolytic effects. Here, we re-examine this therapeutic capacity using Nattokinase as a food additive. A total of 45 male and female participants consumed 219 mg/day of NSK-SD fermented soybean extract (equivalent to 4,000 FU) or one of two different placebos once a day for 8 weeks. Subjects had physiological parameters representative of fibrinolytic activity assessed by a pre-test, after 4 weeks, and after 8 weeks. Results indicated that the diet incorporating Nattokinase did not have a significant impact compared to placebo. However, when limited to participants with a BMI above average (25-28) at the pre-test, total PAI-1 significantly decreased in the experimental group after 8 weeks when compared to the P1 placebo group. Additionally, Nattokinase as a food additive resulted in no adverse health effects.

 Keywords: Nattokinase; Fibrinolytic; Dietary Supplement; Food Addictive; Platelet Aggregation

1. Kumar SS SA. “Fibrinolytic enzymes for thrombolytic therapy”. In: N L, ed. Therapeutic Enzymes: Function and Clinical Implications. Advances in Experimental Medicine and Biology. Volume 1148. Singapore: Springer (2019).
2. Arnout J HM and Lijnen HR. “Haemostasis”. In: Moncada S HA, ed. The vascular endothelium II. Handbook of experimental pharmacology. Volume 176/II. Berlin: Springer (2006): 1-41.
3. Urano T., et al. “The profibrinolytic enzyme subtilisin NAT purified from Bacillus subtilis cleaves and inactivates plasminogen activator inhibitor type 1”. Journal of Biological Chemistry27 (2001): 24690-24696.
4. Tai M-W and Sweet BV. “Nattokinase for prevention of thrombosis”. American Journal of Health-System Pharmacy12 (2006): 1121-1123.
5. Sumi H., et al. “A novel fibrinolytic enzyme (Nattokinase) in the vegetable cheese Natto a typical and popular soybean food in the Japanese diet”. Experientia10 (1987): 1110-1111.
6. Fujita M., et al. “Purification and characterization of a strong fibrinolytic enzyme (Nattokinase) in the vegetable cheese natto, a popular soybean fermented food in Japan”. Biochemical and Biophysical Research Communications3 (1993): 1340-1347.
7. Xu J., et al. “Thrombolytic effects in vivo of Nattokinase in a carrageenan-induced rat model of thrombosis”. Acta Haematologica2 (2014): 247-253.
8. Hsia C-H., et al. “Nattokinase decreases plasma levels of fibrinogen, factor VII, and factor VIII in human subjects”. Nutrition Research3 (2009): 190-196.
9. Hewlings and Kalman.
10. Yoo HJ., et al. “The effects of Nattokinase supplementation on collagen-epinephrine closure time, prothrombin time and activated partial thromboplastin time in nondiabetic and hypercholesterolemic subjects”. Food and Function 5 (2019): 2888-2893.
11. Gaidai O., et al. “Global cardiovascular diseases death rate prediction”. Current Problems in Cardiology 5 (2023): 101622.
12. Johnson RJ., et al. “Redefining metabolic syndrome as a fat storage condition based on studies of comparative physiology”. Obesity (Silver Spring)4 (2013): 659-664.
13. Kirichenko TA-O., et al. “The role of adipokines in inflammatory mechanisms of obesity”. International Journal of Molecular Sciences 23 (2022): 14982.
14. Sillen MA-O and Declerck PA-O. “A narrative review on plasminogen activator inhibitor-1 and its (patho)physiological role: to target or not to target?” International Journal of Molecular Sciences 5 (2021): 2721.
15. Alessi MC and Juhan-Vague I. “PAI-1 and the metabolic syndrome: links, causes, and consequences”. Arteriosclerosis, Thrombosis, and Vascular Biology10 (2006): 2200-2207.
16. Praetner M., et al. “Plasminogen activator inhibitor-1 promotes neutrophil infiltration and tissue injury on ischemia-reperfusion”. Arteriosclerosis, Thrombosis, and Vascular Biology4 (2018): 829-842.
17. Alessi MC., et al. “Plasminogen activator inhibitor 1, transforming growth factor-beta1, and BMI are closely associated in human adipose tissue during morbid obesity”. Diabetes 8 (2000): 1374-1380.
18. Mertens I., et al. “Among inflammation and coagulation markers, PAI-1 is a true component of the metabolic syndrome”. International Journal of Obesity (London) 8 (2006): 1308-1314.
19. Skiba DS., et al. “Anti-atherosclerotic effect of the angiotensin 1-7 mimetic AVE0991 is mediated by inhibition of perivascular and plaque inflammation in early atherosclerosis”. British Journal of Pharmacology 22 (2017): 4055-4069.
20. Weng Y., et al. “Nattokinase: An oral antithrombotic agent for the prevention of cardiovascular disease”. International Journal of Molecular Sciences3 (2017): 523.
21. Fujita M., et al. “Transport of Nattokinase across the rat intestinal tract”. Biological and Pharmaceutical Bulletin9 (1995): 1194-1196.
22. Fujita M., et al. “Antihypertensive effects of continuous oral administration of Nattokinase and its fragments in spontaneously hypertensive rats”. Biological and Pharmaceutical Bulletin 11 (2011): 1696-1701.
23. Nara N., et al. “A single dose of oral Nattokinase accelerates skin temperature recovery after cold water immersion: A double-blind, placebo-controlled crossover study”. Heliyon7 (2023): e17951.
24. Chen H., et al. “Effective management of atherosclerosis progress and hyperlipidemia with Nattokinase: A clinical study with 1,062 participants”. Frontiers in Cardiovascular Medicine 9 (2022): 964977.